



**HAL**  
open science

## Rapid diagnosis of *Clostridium difficile* infection by multiplex real-time PCR.

Frédéric Barbut, Marc Monot, Antoine Rousseau, Sébastien Cavelot, Tabassome Simon, Béatrice Burghoffer, Valérie Lalande, Jacques Tankovic, Jean-Claude Petit, Bruno Dupuy, et al.

### ► To cite this version:

Frédéric Barbut, Marc Monot, Antoine Rousseau, Sébastien Cavelot, Tabassome Simon, et al.. Rapid diagnosis of *Clostridium difficile* infection by multiplex real-time PCR.: Diagnosis of *Clostridium difficile* Infection and Identification of the Epidemic clone 027 by Multiplex Real-Time PCR. (Titre fichier auteur). *European Journal of Clinical Microbiology and Infectious Diseases*, 2011, 30 (10), pp.1279-85. 10.1007/s10096-011-1224-z . pasteur-01370849

**HAL Id: pasteur-01370849**

**<https://pasteur.hal.science/pasteur-01370849>**

Submitted on 23 Sep 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

1 **Diagnosis of *Clostridium difficile* Infection and Identification of the Epidemic clone 027**  
2 **by Multiplex Real-Time PCR**

3

4 **Frédéric Barbut<sup>1\*</sup>, Marc Monot<sup>2\*</sup>, Alexandra Rousseau<sup>3</sup>, Sébastien Cavelot<sup>1</sup>, Tabassome**  
5 **Simon<sup>3</sup>, Béatrice Burghoffer<sup>1</sup>, Valérie Lalande<sup>1</sup>, Jacques Tankovic<sup>1</sup>, Jean-Claude Petit<sup>1</sup>,**  
6 **Bruno Dupuy<sup>2</sup> and C. Eckert<sup>1</sup>**

7 <sup>1</sup>National Reference Laboratory for *C. difficile*, Paris VI University, Paris, France

8 <sup>2</sup>laboratoire Pathogénèse des bactéries anaérobies, Institut Pasteur, Paris, France

9 <sup>3</sup>Clinical Research Unit, Department of Pharmacology, Assistance Publique-Hôpitaux de  
10 Paris, Saint-Antoine hospital, Paris VI University, Paris, France

11 \*These authors contributed equally to this work.

12

13 **Corresponding author:**

14 Frédéric Barbut

15 Hôpital Saint-Antoine

16 UHLIN

17 184 rue du faubourg Saint-Antoine

18 75012 Paris

19 France

20 **tel** : +33 1 49 28 30 08

21 **fax** : +33 1 49 28 30 09

22 mail : [frederic.barbut@sat.aphp.fr](mailto:frederic.barbut@sat.aphp.fr)

23

24 **Short title** : *C. difficile* toxin B detection by real-time PCR

25 **Key words** : *Clostridium difficile*, diagnostics, real-time PCR, toxins

26

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

**Abstract**

Rapid detection of toxigenic *Clostridium difficile* strains is crucial for optimal management of patient with *C. difficile* infection (CDI). Currently, the « gold standards » for the diagnosis of CDI are the cytotoxicity assay and the toxigenic culture. However both methods are time consuming and results are not available before 24-48 hours. The objectives were to develop and evaluate a multiplex in-house real-time PCR for the simultaneous detection of toxigenic strains of *C. difficile* and the presumptive identification of the epidemic NAP1/027/BI strain from stools. Genomic DNA was extracted from stools using the NucliSENS miniMAG Platform (bioMérieux, La Balme-les-Grottes, France). Amplifications were performed using specific primers for *tcdB* and *tcdC* on ABI Prism 7300 (Applied Biosystem). Detection of amplicons was done using TaqMan probes. Analytical sensitivity of the multiplex real-time PCR for detecting *tcdB* was estimated to 10 UFC/g of stools. This assay was assessed from 881 consecutive unformed stools from patients suspected of having CDI. The gold standard was the toxigenic culture for the diagnosis of CDI, and PCR ribotyping for the identification of the NAP1/027/BI strain. The prevalence of positive toxigenic culture was 9.31%. Compared to the toxigenic culture, the sensitivity, specificity, positive and negative predictive values were 86.59%, 97.43%, 78.02% and 98.57% for the real-time PCR and 70.73%, 100%, 100% and 97.08% for the cytotoxicity assay. The epidemic clone NAP1/027/BI was neither detected by real-time PCR nor by the gold standard assay. These results indicated that our in-house real-time PCR assay was more rapid and sensitive than the cytotoxicity assay for the detection of toxigenic *C. difficile* from stool samples.

# 1 INTRODUCTION

2

3 *Clostridium difficile* is currently responsible for 10 to 25% of cases of antibiotic-associated  
4 diarrhea and for virtually all cases of pseudomembranous colitis (PMC)(7, 20, 23). This spore  
5 forming bacterium has also emerged as the leading infectious cause of healthcare-associated  
6 diarrhea in adult patients. The epidemiology of *C. difficile* infections (CDI) has dramatically  
7 changed over the last decade (3, 13, 18, 39). Infections have been reported more frequent and  
8 more severe both in North America and Europe (6, 24, 28, 30). This trend is assumed to be  
9 due in part to the rapid emergence and spread of a specific hypervirulent clone of *C. difficile*  
10 belonging to PCR ribotype 027 (also characterized as toxinotype III, North America PFGE  
11 pulsotype 1 [NAP1] and restriction endonuclease analysis group BI). This clone has been  
12 shown to overproduce *in vitro* both toxins A and B. The overproduction was suggested to be  
13 related to the absence of functional TcdC, the negative regulator of toxin gene expression (27)  
14 by a single nucleotide deletion at position 117 in TcdC encoding gene (42). The NAP1/027/BI  
15 strain also produces a third toxin (binary toxin) and high quantity of spores, which  
16 disseminate easily in the hospital environment (2, 29).

17

18 Prompt diagnosis of CDI is essential not only for patient management but also for swift  
19 implementation of control measures. Historically, the cytotoxicity assay has been considered  
20 as the « gold standard » for the diagnosis of *C. difficile* infections (11). However this method  
21 is time consuming, needs an incubation of at least 24h, and requires cell culture facilities.  
22 More recently, the toxigenic culture has been re-accepted as a gold standard (14, 15). But  
23 again, this technique is too long to be clinically useful. As of today, most laboratories have  
24 adopted enzyme immunoassays for toxins A and B in routine (5). These assays are easier to  
25 perform, more rapid and do not require specific technical skill. However they are not sensitive

1 enough to be used as a stand-alone test for *C. difficile* diagnosis (14, 15, 17, 32). More  
2 recently, real-time PCR assays have been developed in order to overcome the lack of  
3 sensitivity of EIAs and to reduce the time of culture. These assays include in-house real-time  
4 PCR as well as Food and Drug Administration (FDA)-cleared commercial assays. Numerous  
5 clinical studies have shown that these assays exhibit the best concordance with the results of  
6 toxigenic culture as compared to enzyme immunoassays and could represent therefore a  
7 promising alternative for the diagnosis of CDI (17, 22, 25, 31, 35-38).

8 The purpose of this study was to develop and to evaluate a multiplex real-time PCR for both  
9 the detection of toxigenic *C. difficile* strains from stools and the presumptive identification of  
10 NAP1/027/BI strain.

11 (This work was presented at the 50th ICAAC meeting, Boston, 12 to 15 September 2010).

12

13

## 14 **MATERIALS AND METHODS**

15

### 16 **Bacterial strains**

17 Bacterial strains were obtained from the national reference laboratory for *C. difficile* (Paris,  
18 France), from the Pasteur Institute (B. Dupuy, laboratoire Pathogénèse des bactéries  
19 anaérobies) and from Hines VA (S. Sambol, Hines, Illinois, USA). Sixty eight *C. difficile*  
20 strains were studied for the development of the real-time PCR including one non toxigenic  
21 strains (ATCC 43597), and 67 toxigenic strains from toxinotype 0 (n=10 including VPI  
22 10463), I (n=1), III (n=32 including CIP 107932), IV (n=4 including CIP 109239), V (n=4  
23 including CIP109238), VI (n=5), VII (n=1), VIII (n=3), IX (n=1), XII (n=3), XIV (n=1), XX  
24 (n=1), XXIV (n=1). All strains from toxinotype III were characterized by PCR-ribotyping and  
25 *tcdC* sequencing. The analytical specificity of the assay was tested using 8 *Clostridium* spp.

1 other than *C. difficile*: *C. bifermentans* (ATCC 638), *C. amygdalinum* (gift from MR Popoff,  
2 Institut Pasteur), *C. innocuum* (NCIB 10674), *C. ramosum* (ATCC 25582), *C. sordellii* (NCIB  
3 10717), *C. perfringens* (CIP 103409), *C. tertium* (ATCC 14573) and *C. sphenoides* (ATCC  
4 19403). DNA from strains was extracted with the Instagene Matrix kit (Bio-Rad, Ivry,  
5 France), as previously described (6).

6

## 7 **Study population and sample collection**

8 This prospective study was approved by the Comité de Protection des Personnes from Saint-  
9 Antoine Hospital and by the Commission Nationale de l'Informatique et des Libertés (CNIL  
10 N° 1193577). Eligible patients included those with a suspected CDI for whom unformed  
11 stools specimens were submitted by physicians to the laboratory for *C. difficile* testing.  
12 Duplicate specimens (defined by stools samples from the same patient within a period of 10  
13 days) and specimens from patients under 18 years of age were excluded.

14 Eight hundred and eighty one consecutive diarrheal stool samples (stools taking the shape of  
15 the container) were collected from May 2008 to February 2009 from patients hospitalized in  
16 four different university-affiliated hospitals in Paris (Tenon hospital, n=44; Saint-Antoine  
17 hospital, n=392 ; Pitié-Salpêtrière hospital, n=287) and surrounding (C. Foix/J. Rostang  
18 hospital, n=158). Stool samples were stored at +4°C until processing and analysis were done  
19 within 48 h of collection. Specimens were homogenized and then split: a portion of the  
20 specimen was used to test for PCR, culture and cytotoxicity assay. The remaining unformed  
21 stool was frozen at -80°C for subsequent controls.

22 Additionally, five frozen stools from patients having a documented CDI due to 027 strain  
23 were also investigated (obtained from J.P. Canonne, Hôpital de Lens, France).

24

## 25 **Stool processing for real-time PCR**

1 DNA extraction was performed using the NucliSENS miniMAG Platform (bioMérieux, La  
2 Balme-les-Grottes, France) according to the manufacturer's instructions. Stools were diluted  
3 1:20 in sterile PBS and homogenized. Two hundred microliters of this dilution were mixed  
4 with 2 ml of Nuclisens Lysis Buffer and 5 µl of rv3865-containing plasmid (0,03 ng/µl). The  
5 nucleic acid extraction method was based on high-affinity magnetic silica particles. Briefly,  
6 under high salt conditions, nucleic acid binds to the silica particles. These silica particles act  
7 as a solid phase and non-nucleic acid components are removed by several washing steps  
8 performed in the NucliSens miniMAG disposable plastic tray. Finally, nucleic acids are eluted  
9 from the solid phase and the eluate is stored at +4°C until use.

10

### 11 **Real-time PCR**

12 Amplifications were performed either from purified genomic DNA or from crude DNA  
13 extracted from feces samples. A multiplex real-time PCR was developed for the simultaneous  
14 detection of the *tcdB* gene, the deletion at position 117 of *tcdC* gene and a DNA internal  
15 control. The internal control consisted of a plasmid containing part of the gene rv3865 from  
16 *Mycobacterium tuberculosis* (19). The internal control was added on initial processing of  
17 DNA extraction of stool samples. It acts as control of the general process (including DNA  
18 extraction step) and monitors the presence of PCR inhibitors. Primers and probes used in the  
19 assay are described in table 1. Primers and probes for *tcdB* were designed from the non repeat  
20 region of the known *tcdB* sequence (accession number n° NC\_009089) using the Primer 3  
21 software (<http://frodo.wi.mit.edu/primer3/>).

22 Amplification was performed in a 96-well PCR plate in the ABI Prism 7300 real-time PCR  
23 instrument (Applied Biosystems, Roche). A final volume of 20 µl was used containing 2 µl of  
24 extracted DNA, 10µl of TaqMan Master Mix (Roche, Minneapolis), 2 µl Mix containing  
25 Primers (200 nM of each primers except for reference primers (20 nM)), 2 µl Mix containing

1 probes (100 nM of each probes) and water. The reaction was subjected to denaturation at  
2 95°C for 2 min followed by 40 cycles of denaturation at 95°C for 45 s, annealing/elongation  
3 at 60°C for 1 min. Samples were tested in triplicate and negative and positive controls were  
4 included with each run. The positive control was DNA purified from 027/NAP1/BI strain and  
5 the negative control was water. Fluorescent signal was measured at the end of the  
6 annealing/elongation step in each cycle. In case of indeterminate results (defined by one  
7 positive duplicate out of 3) or invalid result (defined by a negative signal with the internal  
8 control), fresh stools were retested including DNA extraction.

9 Real-time PCR, cytotoxicity assay, culture and identification of the epidemic clone  
10 027/NAP1/BI by PCR-ribotyping were performed respectively by 4 different technicians who  
11 were blinded to the results of the other.

12

### 13 **Analytical performances**

14 Detection limit of the multiplex real-time PCR was estimated from ten-fold serial dilutions of  
15 purified genomic DNA from strains 027/NAP1/BI (BI 18). Analytical sensitivity of the real-  
16 time PCR was assessed by spiking 1 g of pooled *C. difficile* culture negative-feces with ten-  
17 fold dilution of different toxigenic strains including CD196, VPI 10463 and ATCC 43598.  
18 Sensitivity of the real-time PCR was compared to culture on TCCA (taurocholate,  
19 cycloserine, cefoxitin agar) medium. Specificity was evaluated from DNA extracted from  
20 different *Clostridium spp.* other than *C. difficile* including *C. bifermentans*, *C. amygdalinum*,  
21 *C. innocuum*, *C. ramosum*, *C. sordellii*, *C. perfringens*, *C. tertium*, and *C. sphenoides*.

22

### 23 **Cell culture cytotoxicity neutralization assay**

24 The cytotoxicity assay was performed using MRC-5 cells. Fresh stool specimens were diluted  
25 in PBS (1:10 [wt/vol]) and centrifuged at 2,500 g for 30 min. The supernatant was passed

1 through a 0.45 µm-pore-size filter and inoculated onto confluent monolayers of MRC-5 cells  
2 in 96-well microtiter plates that were incubated at 37°C in a 6.5% CO<sub>2</sub> atmosphere for 48 h.  
3 The final dilution of the fecal filtrate in each well was 1:100. Samples were considered  
4 positive if a characteristic cytopathic effect (cell rounding) was observed for at least 50% of  
5 the cells and could be neutralized with anti-*Clostridium sordellii* antiserum (obtained from M.  
6 R. Popoff, National Reference Center for Anaerobes, Institut Pasteur, Paris, France). The *in*  
7 *vitro* determination of the cytotoxicity of *C. difficile* isolates was performed by inoculating  
8 two to five colonies into trypticase yeast broth that was incubated 5 days under anaerobic  
9 conditions. The supernatant from this culture was filtered and inoculated on MRC-5 cells as  
10 described above. This method is referred as the toxigenic culture.

11

#### 12 **Direct and enrichment culture**

13 Direct culture was performed on selective medium TCCA (brain heart infusion agar  
14 supplemented with 5% defibrinated horse blood, 0.1% taurocholate, 250 µg/ml cycloserine,  
15 and 10 µg/ml cefoxitin), and plates were incubated for 48 h in an anaerobic atmosphere.  
16 Presumptive identification was based on colony morphology, typical odor, and Gram staining.  
17 Identification was confirmed by use of an enzymatic profile from the RapID32A gallery  
18 (bioMérieux, La Balme les Grottes, France).

19 Stools that were real-time PCR-positive and direct culture-negative were thawed and analyzed  
20 using an enrichment procedure. Briefly, stools were inoculated in pre-reduced taurocholate,  
21 cycloserine-cefoxitin brain heart infusion broth (TCC broth) and incubated for 48h at 37°C in  
22 an anaerobic atmosphere. Then, 100 µl of the broth were subcultured in a second TCC broth,  
23 which was incubated for an additional 48 h in anaerobic atmosphere. Each TCC broth was  
24 plated on TCCA agar. Strains were stored at -80°C in one ml of brain heart infusion broth  
25 containing 10% glycerol.

1

## 2 **Identification of the NAP1/027/BI strain.**

3 The identification of the 027/NAP1/BI was based both on PCR ribotyping and *tcdC*  
4 sequencing.

5 *PCR-ribotyping.* PCR ribotyping consists in a comparison of patterns of PCR products of the  
6 16S-23S rRNA intergenic spacer region, as previously described (9). Briefly PCR reactions  
7 were performed in a 100 µl final volume (50 mM KCl, 10mM Tris-HCl (pH 8.8), 1.5 mM  
8 MgCl<sub>2</sub>, 200 µM of each dNTP, 100 pmol of each primer, 2.5U of *Taq* polymerase and 10 µl  
9 of template DNA). PCR amplifications were performed for 35 cycles of 1 min at 94°C, 1 min  
10 at 57°C, 2 min at 72°C. PCR products were analyzed on a 3% Resophor agarose gel (BioRad,  
11 Ivry, France). An epidemic strain 027/NAP1/BI was used as a control in each run.

12 *TcdC sequencing.* A 343-bp fragment of the *tcdC* gene from toxinotype III strains was  
13 sequenced on an AB3100 DNA sequencer (Applied Biosystems, Foster City, CA). Briefly,  
14 PCR was carried out using the primers *tcdC*-F: GGGAGATTGTATTATGTTTTCTAAA and  
15 *tcdC*-R: CTTTTTTAGCTTCTTCAGCTT. We purified amplified DNA by enzymatic  
16 procedures; 8 µl of PCR products were incubated with 2.5 U of exonuclease I (USB Corp.,  
17 Cleveland, OH) and 0.25 U of shrimp alkaline phosphatase (USB Corp., Cleveland, OH),  
18 with a final volume of 10 µl, at 37°C for 15 min before enzyme inactivation at 80°C for 15  
19 min. Then, we added 2 µl of BigDye v3.1, 4 µl of BigDye v3.1 buffer (Applied Biosystems,  
20 Foster City, CA), and 200 nM of primer for a final volume of 20 µl. The sequencing mixture  
21 was denatured at 96°C for 1 min, followed by 40 cycles of denaturation at 96°C for 30 s,  
22 annealing at 56°C for 15 s, and extension at 60°C for 4 min. Sequences were compiled and  
23 analyzed using Gap4 ([http://staden.sourceforge.net/manual/gap4\\_unix\\_2.html](http://staden.sourceforge.net/manual/gap4_unix_2.html)).

24

## 25 **Statistical methods**

1 Sample size : based on an expected sensitivity and specificity of 90%, alpha of 5% and an  
2 expected prevalence of the disease of 15%, we hypothesize that 927 stool specimens should  
3 be included to estimate sensitivity and specificity with 5% of accuracy.

4 Descriptive analysis was performed with SAS V9 system (SAS Institute, Cary, NC, USA).

5 Specificity, sensitivity, negative and positive predictive values and their 95% confidence  
6 intervals (CI) were calculated using R software version 2.0 (R foundation for statistical  
7 Computing, Vienna, Austria, [www.R-project.org](http://www.R-project.org))

8

1

## 2 **RESULTS**

3

### 4 **Specificity and analytical sensitivity**

5 Sensitivity tests demonstrated that the real-time PCR assay efficiently detected *tcdB* from all  
6 the 67 toxigenic *C. difficile* strains tested. Moreover, deletion at position 117 of the *tcdC* gene  
7 was detected in all the 28 strains from PCR ribotype 027/NAP1/BI and in none of the 40 other  
8 strains. Interestingly, 4 strains of toxinotype III with a PCR-ribotyping pattern close but  
9 different from 027/NAP1/BI strains by at least one faint band, did not harbour the deletion at  
10 position 117, both by *tcdC* sequencing and real-time PCR.

11 The threshold detection of the multiplex real-time PCR for *tcdB* and *tcdC* was 10 picograms  
12 of genomic DNA of 027/NAP1/BI strain.

13 Analytical sensitivity of the multiplex real-time PCR, estimated from spiked fecal specimens  
14 with different concentration of the target bacteria, was 10 CFU per g of stools for *tcdB*, and  
15 100 CFU for *tcdC*.

16 All the 8 *Clostridium spp.* other than *C. difficile* strains tested including *C. sordellii*, which  
17 carries a closely related lethal toxin gene, showed no amplification signal, thereby  
18 demonstrating the specificity of the PCR assay.

19

### 20 **Clinical performances**

21 The prevalence of positive cytotoxicity assay and toxigenic culture were 6.58% (58/881) and  
22 9.31% (82/881), respectively. The overall agreement between the real-time PCR and the  
23 cytotoxicity assay was 95.45%. Using the cytotoxicity assay as a gold standard, the  
24 sensitivity, specificity, positive and negative predictive values of real-time PCR were 94.83%

1 (95% CI, 89.13 to 100%), 95.5% (95% CI, 94.06 to 96.94%), 60.44% (95% CI, 50.39 to  
2 70.49%) and 99.61% (95% CI, 99.18 to 100), respectively.

3 Compared to the toxigenic culture, the sensitivity, specificity, positive and negative predictive  
4 values were 86.59%, 97.43%, 78.02% and 98.57% for the real-time PCR and 70.73%, 100%,  
5 100% and 97.08% for the cytotoxicity assay (table 2).

6 The cycle threshold for the PCR positive-samples for *tcdB* ranged from 25 cycles to 39  
7 cycles, thereby showing a wide variation in the bacterial load of toxigenic *C. difficile* in feces  
8 of patients with CDI.

9 Twenty stool specimens were toxigenic culture-negative and real-time PCR positive. Among  
10 them, 14 were thawed and processed to enriched culture in selective broth and 5 (35.7%)  
11 turned out to be positive for toxigenic *C. difficile*.

12 Conversely, 11 stool specimens were toxigenic culture-positive and real-time PCR negative.  
13 DNA from the corresponding isolates was extracted and used for real-time PCR  
14 amplifications and all were positive for *tcdB*.

15 Real-time PCR for detecting *tcdB* gave indeterminate and invalid results in 10 (1.14%) and 43  
16 (4.88%) cases, respectively. After repeated testing, these figures dropped to 1 (0.11%) and 20  
17 (2.27%), respectively. All these 21 unresolved results were actually negative with the  
18 cytotoxicity assay and the toxigenic culture. Two stool specimens (0.2%) exhibited  
19 indeterminate result by the cytotoxicity assay due to a non specific cytotoxic effect leading to  
20 a disruption of the cell layer.

21 The epidemic clone 027/NAP1/BI was neither detected by real-time PCR nor by the gold  
22 standard assay. However, the five frozen stool specimens from patients infected with the  
23 epidemic 027 strains gave a positive result for both *tcdB* and *tcdC*.

24

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

**DISCUSSION**

*C. difficile* infection has become a major nosocomial pathogen in many healthcare facilities including hospitals, long term facilities and nursing homes. Therefore a rapid and accurate diagnosis is crucial for appropriate antibiotic therapy and for the timely implementation of infection control measures, more specially in the context of outbreaks of the hypervirulent 027/NAP1/BI strain.

The toxigenic culture is considered as the most sensitive method for the diagnosis of CDI but this method is slow and laborious, often requires 48-72 hours to complete and therefore is unlikely to be adopted by clinical laboratory as the standard method for *C. difficile* testing. Stool cytotoxicity assay, which has been also considered as a gold standard for a long time, is not standardized, needs cell culture facilities, and results are not obtained before 24-48 hours. Nowadays, many laboratories routinely use enzyme immunoassay (EIA) for toxin detection. However clinical trials recently demonstrated that EIAs for toxins A and B are not sensitive enough to be used as a stand-alone technique for the diagnosis of CDI (15, 17, 32, 37, 38). Moreover, their poor sensitivity often encourages physicians to order additional testing following the first EIA-negative result, if suspicion of CDI remains high (10). However, the gain of repeat testing has been shown to be low (1, 10).

To enhance rapidity and sensitivity of CDI diagnosis, experts now recommend to implement a two or three-step algorithm using glutamate dehydrogenase (GDH) detection as a screening method (14, 15). This strategy is based on the high negative predictive value of the GDH detection (33, 40, 43). However this antigen is also found in non-toxigenic *C. difficile* strains and therefore any positive result must be confirmed by a more specific assay detecting toxins. As of today, the choice of confirmation assay is still matter of debates. Some recent clinical

1 trials reported lower sensitivities (between 70% and 88%) for GDH assays (17, 26). Tenover  
2 *et al.* have recently showed that the sensitivity of GDH for the detection of non-027 strains  
3 was significantly lower than real-time PCR, suggesting that the variable sensitivities of GDH  
4 assays might be explained by the hospital-to-hospital variations of *C. difficile* strains (37).  
5 Another study has shown that freezing-thawing of stool sample may also affect GDH  
6 detection (34).

7 Another recent option for the diagnosis of CDI is to use real-time PCR. Thus, we developed a  
8 real-time PCR assay for the rapid detection of all toxigenic strains from fecal samples and the  
9 presumptive identification of the epidemic 027 clone, based on the direct detection of *tcdB*  
10 gene sequence and the single base deletion at nucleotide 117 of the *tcdC* gene. The analytical  
11 sensitivity of this assay was excellent with a detection threshold calculated from spiked fecal  
12 samples of 10 UFC/g of stools for *tcdB* and 100 UFC/g stools for *tcdC*. This detection limit is  
13 much lower than those previously reported by Belanger *et al.* ( $5 \cdot 10^4$  CFU/g of stools) or van  
14 den Berg ( $10^5$  CFU/g of stools) (8, 41).

15 To date, four different amplification assays have been recently cleared by the FDA for  
16 laboratory use in the US. These assays target *tcdB* (ProGastro Cd, Prodesse; BD GeneOhm *C.*  
17 *diff*, BD Diagnostics), *tcdA* (Illumigene Meridian) or *tcdB* in combination with binary toxin  
18 and deletion of *tcdC* (Xpert *C. difficile*, Cepheid). These assays have been compared to  
19 toxigenic culture in several clinical trials. A review of clinical performances indicated that  
20 their sensitivity and specificity range from 77.3% to 97.1% and 93% to 100%, respectively  
21 (table 3) (4, 17, 22, 25, 31, 35-38). The performance characteristics of our in-house real-time  
22 PCR assay are in agreement with those data, with a sensitivity and a specificity of 86.6 and  
23 97.4%, respectively. It performs better than the cytotoxicity assay when using the toxigenic  
24 culture as the gold standard method.

1 Among the 20 specimens that were PCR-positive but toxigenic culture-negative, 14 were  
2 cultured using an enrichment method. Interestingly, among these, 5 (35.7%) appeared to be  
3 true positive by enriched toxigenic culture. The corrected sensitivity and specificity of the  
4 real-time PCR would be 87.3% and 98.05%, respectively. The reasons why direct toxigenic  
5 culture appeared negative could include a low concentration of microorganisms in very  
6 heterogeneous sample or a growth inhibition due to previous therapy for *C. difficile*.

7

8 The hands-on technologist time of our real-time PCR is about approximately 30 min., which  
9 is similar to other types of detection assays used for *C. difficile* (cytotoxicity assay, EIA). To  
10 date, the only test that showed a significant shorter hands-on-time is the Gene Xpert *C. diff*  
11 (Cepheid) where DNA extraction and PCR reaction are fully automated and performed in the  
12 same cartridge (22, 37). Another main advantage of real-time PCR is the rapid turn-around  
13 time. Specimen processing, miniMag extraction and testing by the real-time PCR took  
14 approximately 3 hours before the results were reported. This time is considerably shorter than  
15 the 24-48h for the cytotoxicity assay and much shorter than the 3-5 days for the toxigenic  
16 culture.

17

18 The real-time PCR assay we developed may rise several questions.

19 First, there is a practical concern regarding the clinical specificity of this assay. Actually, real-  
20 time PCR is able to detect toxin genes but not the toxin itself. Because asymptomatic carriage  
21 of toxigenic strains is proportional to the length of stay and may reach 50% after 4 weeks of  
22 hospitalization (12), the clinical significance of toxigenic strain remains uncertain. However,  
23 whereas it is true that the isolation of a toxigenic strain of *C. difficile* does not prove that the  
24 patient is infected, it is also true that it is the most likely cause of the diarrhea (16, 21). The  
25 risk of real-time PCR as well as toxigenic culture is to treat by excess patients who are simply

1 colonized by a toxin producing strain. Microbiologists should be aware of this limitation  
2 when interpreting the result.

3 The second limitation is the potential genetic change in *tcdB* gene or the emergence of *tcdA*<sup>+</sup>  
4 *tcdB*<sup>-</sup> strains, resulting in false negative results. To date, these trends are still hypothetical and  
5 the emergence of new genotypes affecting clinical performances of real-time PCR for *tcdB*  
6 remains undocumented. Nevertheless, it will be important to periodically monitor the  
7 emergence of new genotypes, which could negatively impact performances of *tcdB*-based  
8 assays. During the development of our real-time PCR, we have tested our primers and probes  
9 on 68 strains including the most common toxinotypes and all were positive. Moreover, strains  
10 isolated from toxigenic culture-positive and real-time PCR-negative stools, tested positive  
11 when DNA from these strains was used as template for PCR, suggesting that false negative  
12 results were not associated with a mismatch of primers and/or probes.

13 The third limitation of our real time PCR assay is the high rate (6.01%) of unresolved results  
14 upon initial testing, mainly due to a negative result for the internal control. That might be  
15 explained either by an inhibition of PCR reaction or by DNA extraction failure. The rate  
16 dropped to 2.38% after repeated testing. A review of the recent literature indicated that the  
17 rate of unresolved results with other commercially available real-time PCR are similar and  
18 range from 0% to 3.3%. However, it should be emphasized that some PCR-based methods  
19 commercially available do not have an internal control for DNA extraction (BD GeneOhm *C.*  
20 *diff*), and therefore cannot delineate true negative result from DNA extraction failure.

21

22 During the clinical trial, the epidemic 027/NAP1/BI strain was not detected. This result is in  
23 agreement with a recent national survey of *C. difficile* infection where 027 represented only  
24 3.6% (8/224) of all isolates (Eckert C. et al., 50<sup>th</sup> ICAAC, Boston, 12-15 September 2010). As  
25 a consequence, the sensitivity of our real-time PCR for the identification of the 027/NAP1/BI

1 strain could not be calculated. Nevertheless no false positive result in *tcdC* was observed,  
2 suggesting that the specificity of the real-time PCR for *tcdC* deletion was 100%. It also  
3 suggests that the deletion at nt 117 is not found in other strains of *C. difficile* and remains  
4 specific of the epidemic 027/NAP1/BI strain. To overcome the lack of 027/NAP1/BI strains  
5 in our population, the real-time PCR was performed from 5 frozen stools of patients infected  
6 by the 027/NAP1/BI and all were positive both for *tcdB* and *tcdC*. Among the commercial  
7 multiplex real-time PCR assays, only the Xpert *C. difficile* (Cepheid) is able to detect the  
8 presumptive PCR-ribotype 027 strain with a sensitivity and specificity of 100 and 98.1%,  
9 respectively (22).

10

11

12 In summary, our data suggest that sensitivity and specificity of our real-time PCR are  
13 comparable to those of commercially available real-time PCR. The rapid turn-around time of  
14 real-time PCR would allow laboratories to speed up the detection of toxigenic strains and  
15 consequently to improve management of patients with CDI. However, the savings realized  
16 with a rapid and accurate diagnostic method should be further evaluated.

17

18

### 19 **Acknowledgements**

20 This study was supported by a grant from the Programme Hospitalier de Recherche Clinique  
21 (AOR06006). The authors are grateful to Guillaume Arlet, Vincent Jarlier and Alexandra  
22 Aubry for providing stool specimens from patients suspected of having CDI and Jean Pierre  
23 Canonne for providing stool specimens from patients infected by the 027/NAP1/BI strain.

24

25

## 1 References

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

1. **Aichinger, E., C. D. Schleck, W. S. Harmsen, L. M. Nyre, and R. Patel.** 2008. Nonutility of repeat laboratory testing for detection of *Clostridium difficile* by use of PCR or enzyme immunoassay. *J Clin Microbiol* **46**:3795-7.
2. **Akerlund, T., I. Persson, M. Unemo, T. Noren, B. Svenungsson, M. Wullt, and L. G. Burman.** 2008. Increased sporulation rate of epidemic *Clostridium difficile* Type 027/NAP1. *J Clin Microbiol* **46**:1530-3.
3. **Archibald, L. K., S. N. Banerjee, and W. R. Jarvis.** 2004. Secular trends in hospital-acquired *Clostridium difficile* disease in the United States, 1987-2001. *J Infect Dis* **189**:1585-9.
4. **Barbut, F., M. Braun, B. Burghoffer, V. Lalande, and C. Eckert.** 2009. Rapid detection of toxigenic strains of *Clostridium difficile* in diarrheal stools by real-time PCR. *J Clin Microbiol* **47**:1276-7.
5. **Barbut, F., M. Delmee, J. S. Brazier, J. C. Petit, I. R. Poxton, M. Rupnik, V. Lalande, C. Schneider, P. Mastrantonio, R. Alonso, E. Kuijper, and M. Tvede.** 2003. A European survey of diagnostic methods and testing protocols for *Clostridium difficile*. *Clin Microbiol Infect* **9**:989-96.
6. **Barbut, F., P. Mastrantonio, M. Delmee, J. Brazier, E. Kuijper, and I. Poxton.** 2007. Prospective study of *Clostridium difficile* infections in Europe with phenotypic and genotypic characterisation of the isolates. *Clin Microbiol Infect* **13**:1048-57.
7. **Bartlett, J. G.** 2008. Historical perspectives on studies of *Clostridium difficile* and *C. difficile* infection. *Clin Infect Dis* **46 Suppl 1**:S4-11.
8. **Belanger, S. D., M. Boissinot, N. Clairoux, F. J. Picard, and M. G. Bergeron.** 2003. Rapid detection of *Clostridium difficile* in feces by real-time PCR. *J Clin Microbiol* **41**:730-4.
9. **Bidet, P., F. Barbut, V. Lalande, B. Burghoffer, and J. C. Petit.** 1999. Development of a new PCR-ribotyping method for *Clostridium difficile* based on ribosomal RNA gene sequencing. *FEMS Microbiol Lett* **175**:261-6.
10. **Cardona, D. M., and K. H. Rand.** 2008. Evaluation of repeat *Clostridium difficile* enzyme immunoassay testing. *J Clin Microbiol* **46**:3686-9.
11. **Chang, T. W., S. L. Gorbach, and J. B. Bartlett.** 1978. Neutralization of *Clostridium difficile* toxin by *Clostridium sordellii* antitoxins. *Infect Immun* **22**:418-22.
12. **Clabots, C. R., S. Johnson, M. M. Olson, L. R. Peterson, and D. N. Gerding.** 1992. Acquisition of *Clostridium difficile* by hospitalized patients: evidence for colonized new admissions as a source of infection. *J Infect Dis* **166**:561-7.
13. **Cohen, M. B.** 2009. *Clostridium difficile* infections: emerging epidemiology and new treatments. *J Pediatr Gastroenterol Nutr* **48 Suppl 2**:S63-5.
14. **Cohen, S. H., D. N. Gerding, S. Johnson, C. P. Kelly, V. G. Loo, L. C. McDonald, J. Pepin, and M. H. Wilcox.** 2010. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* **31**:431-55.
15. **Crobach, M. J., O. M. Dekkers, M. H. Wilcox, and E. J. Kuijper.** 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and

- 1 recommendations for diagnosing *Clostridium difficile*-infection (CDI). Clin Microbiol  
2 Infect **15**:1053-66.
- 3 16. **Delmee, M., J. Van Broeck, A. Simon, M. Janssens, and V. Avesani.** 2005.  
4 Laboratory diagnosis of *Clostridium difficile*-associated diarrhoea: a plea for culture. J  
5 Med Microbiol **54**:187-91.
- 6 17. **Eastwood, K., P. Else, A. Charlett, and M. Wilcox.** 2009. Comparison of nine  
7 commercially available *Clostridium difficile* toxin detection assays, a real-time PCR  
8 assay for *C. difficile* tcdB, and a glutamate dehydrogenase detection assay to cytotoxin  
9 testing and cytotoxigenic culture methods. J Clin Microbiol **47**:3211-7.
- 10 18. **Freeman, J., M. P. Bauer, S. D. Baines, J. Corver, W. N. Fawley, B. Goorhuis, E.  
11 J. Kuijper, and M. H. Wilcox.** 2010. The changing epidemiology of *Clostridium*  
12 *difficile* infections. Clin Microbiol Rev **23**:529-49.
- 13 19. **Frigui, W., D. Bottai, L. Majlessi, M. Monot, E. Josselin, P. Brodin, T. Garnier,  
14 B. Gicquel, C. Martin, C. Leclerc, S. T. Cole, and R. Brosch.** 2008. Control of *M.*  
15 *tuberculosis* ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog  
16 **4**:e33.
- 17 20. **Gerding, D. N.** 2009. *Clostridium difficile* 30 years on: what has, or has not, changed  
18 and why? Int J Antimicrob Agents **33** Suppl 1:S2-8.
- 19 21. **Gerding, D. N., M. M. Olson, L. R. Peterson, D. G. Teasley, R. L. Gebhard, M. L.  
20 Schwartz, and J. T. Lee, Jr.** 1986. *Clostridium difficile*-associated diarrhea and  
21 colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med  
22 **146**:95-100.
- 23 22. **Huang, H., A. Weintraub, H. Fang, and C. E. Nord.** 2009. Comparison of a  
24 commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for  
25 diagnosis of *Clostridium difficile* infections. J Clin Microbiol **47**:3729-31.
- 26 23. **Kelly, C. P., and J. T. LaMont.** 2008. *Clostridium difficile*--more difficult than ever.  
27 N Engl J Med **359**:1932-40.
- 28 24. **Kuijper, E. J., F. Barbut, J. S. Brazier, N. Kleinkauf, T. Eckmanns, M. L.  
29 Lambert, D. Drudy, F. Fitzpatrick, C. Wiuff, D. J. Brown, J. E. Coia, H. Pituch,  
30 P. Reichert, J. Even, J. Mossong, A. F. Widmer, K. E. Olsen, F. Allerberger, D.  
31 W. Notermans, M. Delmee, B. Coignard, M. Wilcox, B. Patel, R. Frei, E. Nagy, E.  
32 Bouza, M. Marin, T. Akerlund, A. Virolainen-Julkunen, O. Lyytikainen, S.  
33 Kotila, A. Ingebretsen, B. Smyth, P. Rooney, I. R. Poxton, and D. L. Monnet.  
34 2008. Update of *Clostridium difficile* infection due to PCR ribotype 027 in Europe,  
35 2008. Euro Surveill **13**.**
- 36 25. **Kvach, E. J., D. Ferguson, P. F. Riska, and M. L. Landry.** 2010. Comparison of  
37 BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B  
38 enzyme-linked immunosorbent assay for diagnosis of toxigenic *Clostridium difficile*  
39 infection. J Clin Microbiol **48**:109-14.
- 40 26. **Larson, A. M., A. M. Fung, and F. C. Fang.** 2010. Evaluation of tcdB real-time PCR  
41 in a three-step diagnostic algorithm for detection of toxigenic *Clostridium difficile*. J  
42 Clin Microbiol **48**:124-30.
- 43 27. **Matamouros, S., P. England, and B. Dupuy.** 2007. *Clostridium difficile* toxin  
44 expression is inhibited by the novel regulator TcdC. Mol Microbiol **64**:1274-88.
- 45 28. **McDonald, L. C., G. E. Killgore, A. Thompson, R. C. Owens, Jr., S. V. Kazakova,  
46 S. P. Sambol, S. Johnson, and D. N. Gerding.** 2005. An Epidemic, Toxin Gene-  
47 Variant Strain of *Clostridium difficile*. N Engl J Med **353**:2433-41.
- 48 29. **Merrigan, M., A. Venugopal, M. Mallozzi, B. Roxas, V. K. Viswanathan, S.  
49 Johnson, D. N. Gerding, and G. Vedantam.** 2010. Human Hypervirulent

- 1 *Clostridium difficile* Strains Exhibit Increased Sporulation as well as Robust Toxin  
2 Production. J Bacteriol. Ahead of printing
- 3 30. **Muto, C. A., M. Pokrywka, K. Shutt, A. B. Mendelsohn, K. Nouri, K. Posey, T.**  
4 **Roberts, K. Croyle, S. Krystofiak, S. Patel-Brown, A. W. Pasculle, D. L.**  
5 **Paterson, M. Saul, and L. H. Harrison.** 2005. A large outbreak of *Clostridium*  
6 *difficile*-associated disease with an unexpected proportion of deaths and colectomies at  
7 a teaching hospital following increased fluoroquinolone use. Infect Control Hosp  
8 Epidemiol **26**:273-80.
- 9 31. **Novak-Weekley, S. M., E. M. Marlowe, J. M. Miller, J. Cumpio, J. H. Nomura, P.**  
10 **H. Vance, and A. Weissfeld.** 2010. *Clostridium difficile* testing in the clinical  
11 laboratory by use of multiple testing algorithms. J Clin Microbiol **48**:889-93.
- 12 32. **Planche, T., A. Aghaizu, R. Holliman, P. Riley, J. Poloniecki, A. Breathnach, and**  
13 **S. Krishna.** 2008. Diagnosis of *Clostridium difficile* infection by toxin detection kits:  
14 a systematic review. Lancet Infect Dis **8**:777-84.
- 15 33. **Reller, M. E., C. A. Lema, T. M. Perl, M. Cai, T. L. Ross, K. A. Speck, and K. C.**  
16 **Carroll.** 2007. Yield of stool culture with isolate toxin testing versus a two-step  
17 algorithm including stool toxin testing for detection of toxigenic *Clostridium difficile*.  
18 J Clin Microbiol **45**:3601-5.
- 19 34. **Sharp, S. E., L. O. Ruden, J. C. Pohl, P. A. Hatcher, L. M. Jayne, and W. M. Ivie.**  
20 2010. Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate  
21 dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple  
22 diagnosis of *Clostridium difficile* disease. J Clin Microbiol **48**:2082-6.
- 23 35. **Stamper, P. D., R. Alcabasa, D. Aird, W. Babiker, J. Wehrlin, I. Ikpeama, and K.**  
24 **C. Carroll.** 2009. Comparison of a commercial real-time PCR assay for tcdB  
25 detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection  
26 of toxin-producing *Clostridium difficile* in clinical samples. J Clin Microbiol **47**:373-  
27 8.
- 28 36. **Stamper, P. D., W. Babiker, R. Alcabasa, D. Aird, J. Wehrlin, I. Ikpeama, L.**  
29 **Gluck, and K. C. Carroll.** 2009. Evaluation of a new commercial TaqMan PCR  
30 assay for direct detection of the *Clostridium difficile* toxin B gene in clinical stool  
31 specimens. J Clin Microbiol **47**:3846-50.
- 32 37. **Tenover, F. C., S. Novak-Weekley, C. W. Woods, L. R. Peterson, T. Davis, P.**  
33 **Schreckenberger, F. C. Fang, A. Dascal, D. N. Gerding, J. H. Nomura, R. V.**  
34 **Goering, T. Akerlund, A. S. Weissfeld, E. J. Baron, E. Wong, E. M. Marlowe, J.**  
35 **Whitmore, and D. H. Persing.** 2010. Impact of Strain Types on Detection of  
36 Toxigenic *Clostridium difficile*: Comparison of Molecular Diagnostic and Enzyme  
37 Immunoassay Approaches. J Clin Microbiol. Ahead of printing
- 38 38. **Terhes, G., E. Urban, J. Soki, E. Nacs, and E. Nagy.** 2009. Comparison of a rapid  
39 molecular method, the BD GeneOhm Cdiff assay, to the most frequently used  
40 laboratory tests for detection of toxin-producing *Clostridium difficile* in diarrheal  
41 feces. J Clin Microbiol **47**:3478-81.
- 42 39. **Terhes, G., E. Urban, J. Soki, L. Szikra, M. Konkoly-Thege, M. Vollain, and E.**  
43 **Nagy.** 2009. Assessment of changes in the epidemiology of *Clostridium difficile*  
44 isolated from diarrheal patients in Hungary. Anaerobe **15**:237-40.
- 45 40. **Ticehurst, J. R., D. Z. Aird, L. M. Dam, A. P. Borek, J. T. Hargrove, and K. C.**  
46 **Carroll.** 2006. Effective detection of toxigenic *Clostridium difficile* by a two-step  
47 algorithm including tests for antigen and cytotoxin. J Clin Microbiol **44**:1145-9.
- 48 41. **van den Berg, R. J., E. J. Kuijper, L. E. van Coppenraet, and E. C. Claas.** 2006.  
49 Rapid diagnosis of toxinogenic *Clostridium difficile* in faecal samples with internally  
50 controlled real-time PCR. Clin Microbiol Infect **12**:184-6.

- 1 42. **Warny, M., J. Pepin, A. Fang, G. Killgore, A. Thompson, J. Brazier, E. Frost,**  
2 **and L. C. McDonald.** 2005. Toxin production by an emerging strain of *Clostridium*  
3 *difficile* associated with outbreaks of severe disease in North America and Europe.  
4 *Lancet* **366**:1079-84.
- 5 43. **Wolfhagen, M. J., K. Meijer, A. C. Fluit, R. Torensma, R. A. Bruinsma, A. Fler,**  
6 **and J. Verhoef.** 1994. Clinical significance of *Clostridium difficile* and its toxins in  
7 faeces of immunocompromised children. *Gut* **35**:1608-12.  
8  
9  
10  
11

1 **TABLE 1:** Primers and probes used in the PCR assays.

2

Target	Efficiency*	Length	Primer and probe	Sequences
Rv3865	1,74 – 1,90	65 bp	Forward	CGAGTTCAGCTTACCCATGGTT
			Reverse	CAAACCTCTGCAGCGTGTTCATT
			Probe	TTCACGTCGAAATT-NED*
<i>tcdB</i>	1,63 – 1,88	197 bp	Forward	ATGCAGCCAAAGTTGTTGAA
			Reverse	CTGCCATTATACCTATCTTAGCTTC
			Probe	AGTGACCCATTATT-VIC*
<i>tcdC</i>	1,65 – 1,91	145 bp	Forward	GAAATGACCTCCTCATGGTCT
			Reverse	AGTAATGAAAGAAAAGGAAGCTCT AA
			Probe	ACACACCAAATA-FAM*

3 \*Triplex oligos efficiency depends on the number (3 – 1) of targets amplified. *pour coller avec le sens*  
 4 *des efficacités, ex Rv3865 : 1,74 pour triplex (3) et 1,90 pour simplex (1)*

5

6

**TABLE 2** : Performances of cytotoxicity assay and real-time PCR for the detection of toxigenic strains of *C. difficile*.

Assay	Toxigenic culture		Assay performance (95% confidence interval)			
			Sensitivity	Specificity	PPV	NPV
	Negative	Positive	(%)	(%)	(%)	(%)
<b>Cytotoxicity assay</b>						
Negative	797	24	70.7	100	100	97.08
Positive	0	58	(60.88-80.58)		(95.91-98.25)	(96.19-98.35)
Total	797	82				
<b>Real-Time PCR</b>						
Negative	758	11	86.59	97.43	78.02	98.57
Positive	20	71	(79.21-93.97)	(96.32-98.54)	(69.51-86.53)	(97.74-99.4)
Total	778	82				

**TABLE 3** : Comparison of commercially real-time PCR performances for the detection of toxigenic strains of *C. difficile*.

Authors (year)	Assay	Target	No samples	Sensitivity (%)	Specificity (%)	Gold standard	Indet. (%)	Preval. (%)
Barbut F. (2009)			300	93.9	97.7	TC	3.3	11
Stamper P. (2009)			404	83.6	98.2	TC	0.5	15.2
Kvach E. (2010)	BD GeneOhm <i>C. diff</i> assay	<i>tcdB</i>	400	91.4	100	TC	0	26.2
Terhes G. (2009)			600	96.4	99.1	CTA (+TC for discrepant results)	0	9.2
Eastwood K. (2010)			558	88,5	95.4	TC	1.1	18.6
Huang H. (2009)			220	97.1	93	CTA (+ TC for discrepant results)	0	9.2
Tenover F. (2010)	Cepheid Xpert <i>C. diff.</i>	<i>tcdB</i> <i>tcdC</i> binary toxin gene	2296 (multicenter)	93.5	94	Enriched TC	0.4	14.7
Novak-Weekley S. (2010)			432	94.4	96.3	TC	0.9	19.6
Stamper P. (2009)	ProGastro Cd assay (Prodesse)	<i>tcdB</i>	285	77.3	99.2	TC	1.4	15.7
This study		<i>tcdB</i> <i>tcdC</i>	881	86.6	97.4	TC	2.4	9.3

TC: toxigenic culture ; CTA: stool cytotoxicity assay ; Indet.: indeterminate results; Preval.: prevalence